GLP-1s: A Plain-Language Guide to the Drug Class

This page lives in the PlexusDx Education Hub, where we unpack GLP-1 biology, weight-management options, and the genetic factors sitting beneath each choice. Open the Peptides & GLP-1 library.

"GLP-1s," in the plural, is how many people now refer to an entire family of medications. It is a loose, useful shorthand — but it covers several compounds with real differences. This plain-language guide explains what the term points to, the hormone the drugs imitate, how they stretch that signal, the roster of approved options, and the genetics sitting upstream.

What people mean by "GLP-1s"

Used casually, "GLP-1s" refers to the class of GLP-1 receptor agonist medications and, by extension, the GIP/GLP-1 dual agonist tirzepatide. It is a category label rather than a single product. Knowing that the plural spans multiple molecules is the first step toward understanding why they are not all interchangeable.

The hormone the class copies

At the center sits glucagon-like peptide-1, an incretin hormone made by enteroendocrine L-cells in the small intestine in response to food. It triggers glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety in the hypothalamus. The catch is its very short half-life — a matter of minutes — because DPP-4 degrades it rapidly.

How the drugs stretch the signal

GLP-1 receptor agonists are peptides — with small molecules now emerging — engineered to engage the receptor while resisting DPP-4, extending the half-life from minutes to hours or days. They deliver the hormone's effects at a pharmacological level: insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. Tirzepatide additionally engages the GIP receptor, adding a second incretin mechanism.

The roster of approved GLP-1s

As of April 2026, the FDA-approved agonists include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy, Rybelsus); lixisenatide was available historically but is discontinued in the U.S. The dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide has Phase 3 data but is not FDA-approved, and oral non-peptide agonists such as orforglipron are in late-stage development.

What they are cleared to treat

Indications vary by product: type 2 diabetes for most, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several, and obstructive sleep apnea in adults with obesity for Zepbound as of December 2024. Certain products also hold pediatric indications. The label decides what is prescribed for which use.

The shared risk profile

Every approved GLP-1 and dual agonist carries the class boxed warning for thyroid C-cell tumor risk seen in rodent studies, with contraindications for medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are the most common and peak during dose escalation; serious reported events include pancreatitis, gallbladder problems, and acute kidney injury tied to dehydration.

Where your genetics enter the conversation

The plural hides a shared truth: every one of these drugs works on the same receptor system your genes help shape. The receptor these drugs bind, GLP1R, varies from person to person in ways that influence receptor density and how efficiently the incretin signal travels downstream. Nearby, FTO shapes appetite regulation and where the body sets its adiposity baseline, MC4R governs satiety signaling inside the hypothalamus and total energy intake, and TCF7L2 is tied to insulin secretion and incretin response.

None of these variants forecast how you will respond to a particular medication, and the analysis is not pharmacogenomic. What they do is describe the metabolic terrain a clinician is working within. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across FTO and MC4R, and TCF7L2 — pathway-level context you bring to a provider conversation, never a prediction of drug response or dose. It is the test before you invest idea applied to metabolic care.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — including Semaglutide Oral and Tirzepatide Injection. It does not sell other GLP-1-category compounds. For the foundational biology, see What is GLP-1?

The bottom line: the plural “GLP-1s” is convenient but imprecise. It spans several molecules with different formats, schedules, and approvals, united by a shared mechanism at the GLP-1 receptor. Treating the term as a category rather than a product — and knowing the biology beneath it — leads to sharper questions for a provider.

Frequently Asked Questions

Are all "GLP-1s" the same drug?

No. The plural covers several compounds — semaglutide, liraglutide, dulaglutide, exenatide, and the dual agonist tirzepatide — with different indications, formats, and schedules. They share a mechanism at the GLP-1 receptor but are not automatically interchangeable, which is why the specific product on a prescription matters.

How do GLP-1s differ from GIP/GLP-1 dual agonists?

Standard GLP-1s engage only the GLP-1 receptor. The dual agonist tirzepatide also activates the GIP receptor, adding a second incretin mechanism. Trial data such as SURPASS and SURMOUNT suggest the dual approach may produce larger mean effects on weight and glucose in some populations.

Who should not take a GLP-1?

Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is contraindicated across the class. Caution also applies with severe gastrointestinal disease or a history of pancreatitis. A provider should review your full history before starting any GLP-1.

Does the genetic test rank the GLP-1s for me?

No. The Precision Peptide Genetic Test never predicts response to any compound in the class. It reads pathway-level variants in FTO and MC4R, and TCF7L2 that describe baseline GLP-1 and energy-balance biology — upstream context that applies across every option, for a provider discussion.

Keep exploring the PlexusDx Education Hub for more GLP-1 and metabolic-health explainers. Return to the Education Hub.